1. Introduction {#sec1-ijerph-17-01656}
===============

The World Health Organization has reported that nearly two billion people are overweight and obese \[[@B1-ijerph-17-01656]\], while 334 million people worldwide have asthma \[[@B2-ijerph-17-01656]\]. The coexistence of both diseases in one person is common, which may result in the negative distinct condition in contrast with other patients \[[@B3-ijerph-17-01656]\]. There is reported evidence that the distribution rate of obesity is significantly increased in asthma patients compared with non-asthmatic controls \[[@B4-ijerph-17-01656]\]. However, although there is a low reported prevalence of asthma in Saudi Arabia, and a recognized number of patients have uncontrolled disease \[[@B5-ijerph-17-01656]\]. A physiological link between asthma and obesity through chronic inflammatory responses has been suggested in the literature. Therefore, weight control is important to manage asthma \[[@B3-ijerph-17-01656]\].

Adipose tissue secretes mediators including adipokines and cytokines, which may harmfully influence the airways. Many reports have revealed the potential role of adiponectin (decreased in obesity) and leptin (elevated in obesity) in allergic asthma \[[@B6-ijerph-17-01656],[@B7-ijerph-17-01656]\]. Bronchial asthma in obese patients differs from other forms of disease in which obese patients present with a severe attack and poor response to steroids. These findings suggest obesity is a causal factor of asthma \[[@B8-ijerph-17-01656],[@B9-ijerph-17-01656]\]. Ghrelin, an endogenous ligand for the growth hormone receptor, counteracts the action of leptin to regulate energy balance \[[@B10-ijerph-17-01656],[@B11-ijerph-17-01656]\]. Plasma levels of ghrelin, mostly originating from the intestines, normally increase before meals, particularly after a long fasting period \[[@B11-ijerph-17-01656],[@B12-ijerph-17-01656],[@B13-ijerph-17-01656]\], whereas the level decreases after carbohydrate and fat meals in rats \[[@B13-ijerph-17-01656]\]. In addition, ghrelin improves airway hyper-responsiveness and asthma symptoms in rats \[[@B14-ijerph-17-01656]\].

There is a strong link between asthma and obesity regarding serum levels of leptin and adiponectin \[[@B15-ijerph-17-01656]\]. Significant higher plasma levels of ghrelin and visfatin in asthmatic patients may imply that ghrelin exerts an anti-inflammatory effect in asthma, suggesting that it might be a new anti-inflammatory drug for asthmatic patients \[[@B16-ijerph-17-01656]\]. However, targeting the ghrelin receptor may induce unacceptable adverse effects and thus may have limited clinical use \[[@B17-ijerph-17-01656]\]. Nonetheless, in another report, there was a strong negative correlation between plasma ghrelin and serum IgE levels, in which ghrelin suppressed IgE production \[[@B18-ijerph-17-01656]\].

This study aimed to identify the correlation between serum levels of ghrelin, obesity, and asthma with the possible role of some associated inflammatory cytokines---particularly IL-4, IL-5 and IL-21---in children to investigate ghrelin as a future target in the management of asthma.

2. Materials and Methods {#sec2-ijerph-17-01656}
========================

2.1. Study Design and Setting {#sec2dot1-ijerph-17-01656}
-----------------------------

This study was a cross-sectional study of a representative sample of Saudi schoolchildren in Najran, Southwestern Saudi Arabia. This work has been carried out in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving human subjects. The Ethics and Research Committee of the College of Medicine, Najran University approved the study protocol. Written informed consent was obtained from the parents or legal guardians of the students.

The sample size was calculated using the formula n = Z^2^P (1-P)/d^2^ \[[@B19-ijerph-17-01656]\], where P is the expected prevalence, estimated as 4.05% in Saudi Arabia (95% confidence interval (CI): 3.54%--4.62%) \[[@B5-ijerph-17-01656]\]. Therefore, the sample size for non-obese asthmatic children was 100, and the same sample size was chosen for obese asthmatics and obese non-asthmatics with 101 children in the control group (non-obese non-asthmatics). The grouping of children into obese and non-obese groups was based on their body mass index (BMI) percentile, because obesity is defined as a BMI greater than the 95th percentile for age and gender. In accordance with the guidelines of The Saudi Initiative for Asthma \[[@B20-ijerph-17-01656]\] and the Global Initiative for Asthma \[[@B21-ijerph-17-01656]\], asthma was diagnosed based on a history of recurrent or chronic chest symptoms such as coughing, wheezing, difficulty breathing, and chest tightness that demonstrated clinical reversibility with short-acting bronchodilator treatment. Symptom score in children with asthma was assessed according to a six-domain asthma symptom score that includes dyspnea, tightness in the chest, wheezing during the day, wheezing during the night, and daily performance \[[@B22-ijerph-17-01656]\].

Children with asthma had not received any anti-inflammatory treatment such as corticosteroids. Children with any other acute or chronic disease, including acute upper or lower respiratory tract infection, were excluded along with children who had received treatment for asthma within the previous 3 months.

2.2. Biochemical Evaluation {#sec2dot2-ijerph-17-01656}
---------------------------

For the determination of ghrelin and interleukins-4, -5 and -21, venous blood (2 mL) was drawn at 9:00 a.m. after an overnight fast. Blood samples were left for 1 h to clot at room temperature. The serum was separated by centrifugation at 1200× *g* for 10 min and stored at −80 °C. Sera were thawed at room temperature before measurement. The serum ghrelin concentrations were measured using the ELISA method (Desacyl-Ghrelin ELISA kit, Abnova, Walnut, CA, USA). The Desacyl-Ghrelin ELISA kit was used for the in vitro quantitative assay of ghrelin peptide based on the competitive enzyme immunoassay principle. IL-4 and IL-5 were measured using Quantikine ELISA (R&D SYSTEMS, Minneapolis, MN, USA) kits, whereas IL-21 was measured using a LifeSpanBioSciences (LS Bio, Seattle, WA, USA) ELISA kit.

2.3. Statistical Analysis {#sec2dot3-ijerph-17-01656}
-------------------------

Data were coded, validated and analysed using the SPSS version 23 software package. Frequency, percentage, arithmetic mean, median and mode were used to present the data. The Mann--Whitney test and Kruskal--Wallis tests were used as tests of significance at a 5% level of significance, while the association between variables was estimated by Pearson's correlation. To identify potential risk factors, binary logistic multivariate analysis, adjusted odds ratio (aOR) and antecedent 95% confidence intervals (CI) were calculated. A receiver operating characteristic (ROC) curve was constructed to examine the predictive performance of bronchial asthma in identifying serum ghrelin level. The graphical plot demonstrated the performance of the cut-off points in terms of sensitivity versus specificity. The area under the curve (AUC) is a measure of the accuracy of a test or cut-off point; the AUC value lies between 0.5 and 1, where less than 0.7 denotes a poor classifier and 1 denotes an excellent classifier.

3. Results {#sec3-ijerph-17-01656}
==========

The present study included 401 Saudi schoolchildren, including 345 males (86.0%) and 56 females (14.0%). Data for the ghrelin values (ng/mL) of the study sample of children ranged from 98 to 236 ng/mL with a mean of 189.18 ± 30.79 ng/mL.

The mean ghrelin values were insignificantly different in obese children (191.7 ± 29.61 ng/mL) compared to non-obese children (186.7.25 ± 31.79 ng/mL) (Mann--Whitney Z = 1.524, *p* = 0.127).

[Table 1](#ijerph-17-01656-t001){ref-type="table"} shows the mean of ghrelin among the four studied groups of children. The four groups differed significantly from each other (Kruskal--Wallis chi-square test = 39.4, *p* = 0.001). The highest values were for non-obese asthmatics, while the lowest values were for non-obese non-asthmatics.

The serum concentrations of ghrelin, IL-4 and IL-21 were significantly increased in asthmatic children compared with non-asthmatic children (*p* \< 0.05), while the serum concentrations of IL-5 were not significantly different among asthmatic children compared to non-asthmatic children (*p* = 0.124; [Table 2](#ijerph-17-01656-t002){ref-type="table"}).

This study included 200 asthmatic children. By using an asthma control questionnaire, the study revealed that 80 children (40%) were not asthma controlled (a score of less than 19), and that the rest were controlled asthmatics. Regarding the control of asthma, the results showed that the mean values of ghrelin, IL-5 and IL-21 among uncontrolled asthmatic children were significantly higher than the corresponding values among controlled-asthmatic children (*p* = 0.002; *p* = 0.001; *p* = 0.001, respectively), while the mean serum IL-4 levels were similar between controlled and uncontrolled asthmatic children ([Table 3](#ijerph-17-01656-t003){ref-type="table"}).

For asthmatic children, the results of Pearson's correlation coefficients revealed a weak positive association between serum ghrelin level and serum levels of IL-4, IL-5 and IL-21 (r = 0.362, *p* ˂ 0.001; r = 0.258, *p* ˂ 0.001; r = 0.168, *p* = 0.018; [Figure 1](#ijerph-17-01656-f001){ref-type="fig"}, [Figure 2](#ijerph-17-01656-f002){ref-type="fig"} and [Figure 3](#ijerph-17-01656-f003){ref-type="fig"} respectively). In non-asthmatic children, there was no significant correlation between serum ghrelin level and the serum levels of IL-4, IL-5 and IL-21 (r = 0.161, *p* = 0.24; r = −0.037, *p* = 0.605; r = 0.086, *p* = 0.231, respectively).

The overall distribution of the ghrelin values showed that the upper quartile (75th percentile values) was 216 ng/mL. Values above or equal to 75th percentile values were regarded as high values. In multivariate logistic regression analysis, the determinants of high ghrelin values were ≥216 ng/mL ([Table 4](#ijerph-17-01656-t004){ref-type="table"}). After adjusting variables to each other, asthma was the only significant risk factor among the studied variables. Asthmatic children had more than twice the risk (aOR = 2.191, 95% CI: 1344 -- 3.571) of having high ghrelin values compared with non-asthmatics.

Serum ghrelin at the optimal cut-off point of 191.5 ng/mL was poor in terms of accurately identifying asthmatic children (AUC = 0.665). Above this point, the test indicated asthma with 68.9% sensitivity and 62.3% specificity.

4. Discussion {#sec4-ijerph-17-01656}
=============

Our study revealed that serum ghrelin, IL-4, and IL-21 levels were significantly increased in asthmatic children compared with non-asthmatic children, and there were significant positive correlations between ghrelin and IL-4, IL-5, and IL-21 in asthmatic children. Ghrelin is a gastric hormone with adipogenic, orexigenic, and somatotropic properties that counteracts leptin in the gastrointestinal regulation of food intake and energy balance. This interaction may have other effects in the lung, especially in asthmatics and obese patients \[[@B23-ijerph-17-01656],[@B24-ijerph-17-01656]\]. In a previous study, leptin levels in obese and non-obese asthmatic children were higher than in matched non-asthmatic controls. Nevertheless, elevated leptin values in the same study were positively correlated with high levels of interferon (INF)-g (Th1 cytokine) that were attributed to inflammation around the bronchioles and the aggravation of severe asthma \[[@B22-ijerph-17-01656]\]. Ghrelin is expected to have anti-inflammatory actions that might suppress proinflammatory cytokines such as tumor necrosis factor (TNF)-α, IL-1β and IL-6, which are involved in the inflammation and pathogenesis of asthma \[[@B25-ijerph-17-01656],[@B26-ijerph-17-01656]\]. There is conflicting information on ghrelin blood levels among obese or non-obese asthmatic children. For example, the role of ghrelin in weight gain in rodents was positively correlated with the administration of synthetic ghrelin, which is in accordance with our current results in humans, whereas the values of blood ghrelin were higher in obese children compared with non-obese children, although the result was not significant (*p* = 0.127). Reports from Taheri et al. and Sanchez-de-La-Torre et al. found a negative correlation between plasma ghrelin levels and BMI \[[@B26-ijerph-17-01656],[@B27-ijerph-17-01656]\]. The differences in the relationship between ghrelin and body weight might be explained by specific research situations. In this study, the mean values of blood ghrelin among asthmatic children were significantly higher than among non-asthmatic children. These results are consistent with previous findings from other studies. Toru et al. and Cobanoglu et al. found that serum levels of ghrelin were significantly higher in asthmatics compared with non-asthmatic controls \[[@B16-ijerph-17-01656],[@B28-ijerph-17-01656]\]. Contrary to these findings, Yuksel et al. evaluated the serum levels of leptin and ghrelin in obese and non-obese children with asthma, as well as healthy controls. The study concluded that the mean ghrelin levels in obese asthmatics were lower than in non-obese asthmatics and the control group (*p* = 0.001) \[[@B23-ijerph-17-01656]\]. Tsaroucha et al. also assessed the circulating concentrations of leptin, adiponectin and ghrelin in asthmatic patients, and they reported that these hormones have roles in the pathogenesis of asthma and its acute state \[[@B24-ijerph-17-01656]\]. Furthermore, a study of ghrelin and leptin levels to investigate immunity modulation among overweight and lean children reported that ghrelin was negatively correlated with serum IgG, IgA, and IgE, while serum IgM showed no correlation between groups \[[@B18-ijerph-17-01656]\]. In addition, ghrelin was shown to inhibit the expression of proinflammatory cytokines induced by leptin \[[@B29-ijerph-17-01656]\] Matsumoto et al. found a low level of ghrelin in asthmatics versus non-asthmatic individuals \[[@B30-ijerph-17-01656]\]. Furthermore, IgE levels were negatively correlated with ghrelin levels in obese children, suggesting that ghrelin directly or indirectly inhibits IgE synthesis. Yuksel et al. \[[@B23-ijerph-17-01656]\] reported that ghrelin levels were not correlated with symptom score or any of the disease severity parameters (r = −0.12, *p* \> 0.05). However, in our study, uncontrolled asthmatics patients showed significantly higher ghrelin values compared with controlled-asthmatic children. The elevated ghrelin levels in this report might explain the competition effect of this hormone against IgE, and proinflammatory cytokines, which are concomitantly increased during asthmatic exacerbations \[[@B23-ijerph-17-01656]\]. The anti-inflammatory role of ghrelin in asthma requires more research to support the recommendations of Toru and colleagues for its use as an anti-inflammatory drug for asthmatic patients \[[@B16-ijerph-17-01656]\]. In this study, we examined the levels of IL-4, IL-5, and IL-21, which are involved in the pathology of asthma. Our results did not differ from previous studies \[[@B31-ijerph-17-01656],[@B32-ijerph-17-01656],[@B33-ijerph-17-01656]\], where IL-4 and IL-21 were significantly elevated in asthmatic children compared with non-asthmatic children, while IL-5 showed an insignificant increase in asthmatic children. IL-4 was associated with IgE production and allergy \[[@B34-ijerph-17-01656]\], and we found that the level of IL-4 increased among uncontrolled asthmatics in contrast to controlled asthmatic patients; however, this was statistically insignificant. Moreover, IL-21 and IL-5 levels were significantly higher in uncontrolled versus controlled asthmatic patients. IL-21 has an anti-allergic effect, evidenced by its role in the remission of allergic rhinitis in mice \[[@B35-ijerph-17-01656]\]. In addition, IL-21 has a regulatory function in humoral and adaptive immunity, where it antagonizes allergic IgE antibodies \[[@B36-ijerph-17-01656]\]. This might explain the occurrence of high levels of IL-21 among uncontrolled asthmatic patients in contrast to non-asthmatics. The concomitant increases of ghrelin and IL-4, IL-5, and IL-21 in uncontrolled asthmatic patients versus the controlled asthmatic group in this study is interesting. IL-4 and IL-5 play a crucial mechanistic role in asthma. They enhance eosinophilic and allergic inflammation, which further results in alterations in the smooth muscle cells, leading to the hyper-secretion of mucus, increased smooth muscle contractility, and airway hyperresponsiveness \[[@B37-ijerph-17-01656]\].

Therefore, we applied further statistical measures to understand this relationship. A positive correlation between ghrelin level and IL-4, IL-5, and IL-21 was determined, but there was no correlation with non-asthmatic patients.

This study suggests that this metabolic hormone might be linked with cytokines in the pathophysiology of asthma, in a similar manner to its positive anti-inflammatory effect on spinal cord injury \[[@B38-ijerph-17-01656]\] and sepsis \[[@B39-ijerph-17-01656]\].

In this study, multiple logistic regression analysis was used to identify the determinants of ghrelin levels above the 75th percentile value of 216 ng/mL after adjusting variables to each other. We found that only asthma was a significant risk factor. Asthmatic children have over twice the risk (aOR = 2.19, 95% CI: 1.34--3.57) of having high ghrelin levels compared with non-asthmatics. However, in contrast to our findings, previous clinical studies found that ghrelin had immunomodulatory activities through the dose- and time-dependent inhibition of IL-1β, IL-6, and TNF-α. Furthermore, ghrelin, in some studies, reduced the levels of proinflammatory adipokines and cytokines from mononuclear and T cells induced by leptin \[[@B23-ijerph-17-01656],[@B27-ijerph-17-01656],[@B28-ijerph-17-01656]\]. The downregulation of these cytokines might be explained by the energy imbalance induced by ghrelin, which interferes with the function of sensitive innate and adaptive immune cells \[[@B28-ijerph-17-01656]\].

Ghrelin was significantly higher among non-obese asthmatics compared to non-obese non-asthmatics, suggesting the impact of asthma on raising the ghrelin level. Similarly, ghrelin was significantly higher among obese non-asthmatics compared to non-obese non-asthmatics, suggesting the impact of obesity in raising the level of this hormone. On the other hand, ghrelin was significantly higher among obese asthmatics compared to non-obese asthmatics, suggesting the additive impact of being both obese and asthmatic. Moreover, and interestingly, there are concomitant increases of ghrelin, IL-4, IL-5, and IL-21 in uncontrolled asthmatic patients versus the controlled asthmatic group, with a direct correlation between ghrelin and these cytokines.

These results suggest the possible protective role of ghrelin on pulmonary airways. It seems that whenever there is a risk or a challenge of increases in airway resistance, such as asthma or obesity, ghrelin levels tend to increase as a compensatory protective mechanism. Therefore, a question regarding the nature of the airway protective mechanism of ghrelin arises: does this occur because of an anti-inflammatory effect? If so, the increase in the serum level of ghrelin should be accompanied by a decrease in IL-4 and IL-5, which was not the case in this study. Therefore, we thought of another possible mechanism; i.e., that ghrelin might have a direct protective effect on airway smooth muscles rather than an anti-inflammatory effect. We conducted an in vitro study on the direct relaxant effect of ghrelin on guinea pig airway smooth muscles on both intact trachea and sensitized one to mimic the asthma model. In this published study, ghrelin has shown a promising relaxing effect on carbachol-contracted tracheal smooth muscles. The effect was more evident in the intact non-sensitized than in sensitized groups (*p* \< 0.05). The effect is suggested to occur partially through an epithelium-dependent mechanism because preincubation with nitric oxide (NO) and prostaglandin E2 (PGE2) inhibitors significantly reduced the ghrelin-induced relaxation. Nevertheless, the relaxing effect was not completely abolished, suggesting an epithelium-independent mechanism \[[@B40-ijerph-17-01656]\]. In the case of reactive airway disease, the airway inflammation might decrease the release of the epithelium-derived factors nitric oxide (NO) and prostaglandin E2 (PGE2) and therefore weaken the direct protective effect of ghrelin. However, ghrelin might act through an epithelium-independent mechanism, which justifies the higher ghrelin levels observed in asthmatic groups. Still, a question needs to be answered: what is the signal for the rise in ghrelin levels in asthma and obesity? Further studies are required to address this.

To understand the effect of ghrelin and cytokines in asthmatic patients, a prospective study that involves the investigation of additional inflammatory mediators and the selection of an appropriate measurement time based on the condition of patients related to a state of hunger or satiety is required. In addition, we must keep the patient's medical status in mind as cytokines increase and decrease in acute cases. A limitation of this study was that ghrelin levels vary during the day in response to hunger and body energy, which may give misleading results. Furthermore, samples were taken from asthmatic patients at various disease stages and different unknown sub-types of asthma, leading to different cytokine expressions. In addition, ghrelin levels were obtained from serum without inclusion of protease inhibitors and this could be a limitation of our study.

5. Conclusions {#sec5-ijerph-17-01656}
==============

This work revealed that serum ghrelin, IL-4, and IL-21 levels were significantly higher among asthmatic children. Interestingly, blood ghrelin, IL-5, and IL-21 levels were significantly higher among uncontrolled asthmatics compared to controlled-asthmatic children. This study also provides further evidence supporting the anti-inflammatory role of ghrelin in the pathogenesis of asthma. In this context, the elevation of either ghrelin and interleukins in asthmatics may highlight the balanced interaction between the anti-inflammatory role of ghrelin and the pro-inflammatory role of some interleukins during uncontrolled asthma. The elevation of both ghrelin and some interleukin levels in asthmatic patients may suggest that ghrelin might act through an epithelium-independent mechanism. Asthma might be considered as an important determinant of high ghrelin values in children.
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ijerph-17-01656-t001_Table 1

###### 

Ghrelin level among different groups of children.

  Variable                  Number   Median   Mean     SD
  ------------------------- -------- -------- -------- -------
  Non-obese non-asthmatic   101      166      174.02   31.23
  Non-obese asthmatic       100      212      199.25   27.13
  Obese non-asthmatic       100      190      186.21   30.99
  Obese asthmatic           100      210      197.43   27.09

ijerph-17-01656-t002_Table 2

###### 

Ghrelin and interleukin levels among the study sample with the presence of bronchial asthma. IL: interleukin.

  Parameter (Median, Mean ± SD)   Asthmatics: N (200)     Non-Asthmatics: N (201)   *p* Value
  ------------------------------- ----------------------- ------------------------- -----------
  Ghrelin, ng/mL                  210, 198.40 ± 27.06     178, 180.10 ± 31.63       0.001 \*
  IL-4, pg/mL                     172.5, 191.02 ± 45.98   163, 175.51 ± 38.52       0.001 \*
  IL-5, pg/mL                     35, 36.51 ± 6.14        34, 35.08 ± 3.58          0.124
  IL-21, µg/mL                    880, 896.20 ± 157.66    824, 843.45 ± 119.16      0.003 \*

\*: *p* \< 0.05.

ijerph-17-01656-t003_Table 3

###### 

Ghrelin and interleukin levels among the study sample by the control of bronchial asthma.

  Parameter (Mean ±SD)   Controlled: N (120)   Uncontrolled: N (80)   *p* Value
  ---------------------- --------------------- ---------------------- -----------
  Ghrelin, ng/mL         193.81 ± 27.51        204.95 ± 25.12         0.002 \*
  IL-4, pg/mL            190.00 ± 48.45        191.10 ± 44.46         0.214
  IL-5, pg/mL            35.51 ± 5.47          38.02 ± 6.77           0.001 \*
  IL-21, µg/mL           857.51 ± 133.10       954.25 ± 173.70        0.001 \*

\*: *p* \< 0.05.

ijerph-17-01656-t004_Table 4

###### 

Multivariate logistic regression analysis of factors determining high ghrelin values.

  Variables                                     aOR     95% CI         *p* Value
  --------------------------------------------- ------- -------------- -----------
  Sex: males vs. females                        0.449   0.179--1.129   0.089
  Obesity: obese vs. non-obese                  1.057   0.669--1.669   0.812
  Asthmatic: Asthmatics vs. non-asthmatics \*   2.191   1.344--3.571   0.002

\*: *p* \< 0.05. aOR; adjusted odds ratio: CI; confidence interval.
